Cardiovascular Systems, Inc. Announces Former U.S. Congressman Erik Paulsen Joins Board of Directors
July 25 2019 - 4:05PM
Business Wire
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical
device company developing and commercializing innovative
interventional treatment systems for patients with peripheral and
coronary artery disease, today announced the addition of
independent board member Erik Paulsen. He replaces director Scott
Bartos, who is retiring from the board after seven years of
service. The CSI board continues to have seven directors, six of
whom are independent.
From 2009 to 2019, Paulsen represented Minnesota’s Third
Congressional District in the United States House of
Representatives. During his tenure, Paulsen was a leading member on
the House Ways and Means Committee, the House’s tax-writing body
with broad jurisdiction over healthcare, economic and trade policy.
He also served as Chairman of Congress’ Joint Economic Committee, a
unique House-Senate panel tasked with working alongside the
President’s Council of Economic Advisors and the Federal Reserve
Board to identify and address macroeconomic trends. Paulsen was
co-chair of the bipartisan House Medical Technology Caucus, as
well. Prior to his service in Congress, Paulsen was a member of the
Minnesota State Legislature, where he served as House Majority
Leader. Paulsen has over 16 years of business experience, including
working as a business analyst at Target Corporation.
“During his time as a member of the United States House of
Representatives, Erik was a strong advocate for the medical
technology industry, the life-saving technologies it provides to
patients and the hundreds of thousands of jobs it supports,” said
Scott Ward, CSI Chairman, President and Chief Executive Officer.
“His leadership and experience in government affairs will be
invaluable as CSI seeks to expand the number of patients it
serves.”
Said Ward, “We thank Scott Bartos for his many contributions to
CSI throughout the past seven years. During his tenure, over
400,000 patients benefitted from orbital atherectomy. Scott’s
counsel helped shape CSI’s strategy as we transform this company
from a single technology, single geography company to an innovative
leader with worldwide reach.”
About Cardiovascular Systems, Inc. Cardiovascular
Systems, Inc., based in St. Paul, Minn., is a medical device
company focused on developing and commercializing innovative
solutions for treating vascular and coronary disease. The company’s
OAS treat calcified and fibrotic plaque in arterial vessels
throughout the leg and heart in a few minutes of treatment time,
and address many of the limitations associated with existing
surgical, catheter and pharmacological treatment alternatives. The
U.S. FDA granted 510(k) clearance for the use of the Diamondback
Orbital Atherectomy System in peripheral arteries in August 2007.
In October 2013, the company received FDA approval for the use of
the Diamondback Orbital Atherectomy System in coronary arteries.
The Stealth 360® Peripheral Orbital Atherectomy System (OAS)
received CE Mark in October 2014. Over 450,000 of CSI’s devices
have been sold to leading institutions worldwide.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190725005002/en/
Cardiovascular Systems, Inc. Jack Nielsen (651) 202-4919
j.nielsen@csi360.com
Padilla: Matt Sullivan (612) 455-1709
matt.sullivan@padillaco.com
Cardiovascular Systems (NASDAQ:CSII)
Historical Stock Chart
From May 2024 to Jun 2024
Cardiovascular Systems (NASDAQ:CSII)
Historical Stock Chart
From Jun 2023 to Jun 2024